middle.news
How AdAlta’s ‘East to West’ CAR-T Strategy Could Transform Solid Cancer Treatment
9:16am on Tuesday 19th of August, 2025 AEST
•
Biotechnology
Read Story
How AdAlta’s ‘East to West’ CAR-T Strategy Could Transform Solid Cancer Treatment
9:16am on Tuesday 19th of August, 2025 AEST
Key Points
In-licensing next-gen CAR-T therapies from Asia for Western clinical development
Two first-in-class CAR-T assets targeting solid cancers progressing toward trials
Anti-fibrotic protein AD-214 completed Phase 1, seeking partners for Phase II
WD-34 pan-strain anti-malarial i-body available for partnering
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Adalta (ASX:1AD)
OPEN ARTICLE